DK1151102T3 - Glycosylerede leptinpræparater og relaterede fremgangsmåder - Google Patents

Glycosylerede leptinpræparater og relaterede fremgangsmåder

Info

Publication number
DK1151102T3
DK1151102T3 DK00911784T DK00911784T DK1151102T3 DK 1151102 T3 DK1151102 T3 DK 1151102T3 DK 00911784 T DK00911784 T DK 00911784T DK 00911784 T DK00911784 T DK 00911784T DK 1151102 T3 DK1151102 T3 DK 1151102T3
Authority
DK
Denmark
Prior art keywords
proteins
glycosylated
glycosylated leptin
leptin
methods
Prior art date
Application number
DK00911784T
Other languages
Danish (da)
English (en)
Inventor
Steven G Elliott
Frances H Martin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK1151102T3 publication Critical patent/DK1151102T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DK00911784T 1999-02-12 2000-02-11 Glycosylerede leptinpræparater og relaterede fremgangsmåder DK1151102T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24967599A 1999-02-12 1999-02-12

Publications (1)

Publication Number Publication Date
DK1151102T3 true DK1151102T3 (da) 2006-05-29

Family

ID=22944511

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00911784T DK1151102T3 (da) 1999-02-12 2000-02-11 Glycosylerede leptinpræparater og relaterede fremgangsmåder

Country Status (11)

Country Link
EP (1) EP1151102B1 (fr)
JP (1) JP4841037B2 (fr)
AT (1) ATE323766T1 (fr)
AU (1) AU781460B2 (fr)
CA (1) CA2359840C (fr)
CY (1) CY1107470T1 (fr)
DE (1) DE60027409T2 (fr)
DK (1) DK1151102T3 (fr)
ES (1) ES2257287T3 (fr)
PT (1) PT1151102E (fr)
WO (1) WO2000047741A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079415A2 (fr) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reduction de l'immunogenicite de proteines de fusion
CA2459015A1 (fr) * 2001-08-29 2003-03-13 The University Of Buckingham Utilisation de leptine chez les enfants de faible poids a la naissance pour la prevention de l'obesite
DE60237100D1 (de) * 2001-10-22 2010-09-02 Amgen Inc Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
US7094579B2 (en) 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
WO2004064750A2 (fr) 2003-01-22 2004-08-05 Duke University Constructions ameliorees permettant d'exprimer des polypeptides lysosomiaux
ATE448312T1 (de) 2003-09-26 2009-11-15 Merck Serono Sa Leitsequenzen zur verwendung bei der produktion von proteinen
EP2586456B1 (fr) 2004-10-29 2016-01-20 ratiopharm GmbH Remodelage et glycopégylation de facteur de croissance de fibroblaste (FGF)
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US8642543B2 (en) 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2008067599A1 (fr) * 2006-12-04 2008-06-12 Apollo Life Sciences Limited Molécules isolées de leptine et d'adiponectine et molécules chimériques de celles-ci
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
JP2009126856A (ja) * 2007-11-28 2009-06-11 Fancl Corp 血中中性脂肪上昇抑制剤
WO2009149379A2 (fr) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Utilisation de leptine pour le traitement de maladies et affections de stéatose hépatique
BR112013007388B1 (pt) 2010-09-28 2022-01-04 Amylin Pharmaceuticals, Llc Polipeptídeo tendo domínio de ligação de albumina e leptina, seu uso no tratamento de doenças, bem como composição farmacêutica que o compreende
KR102434075B1 (ko) 2012-05-17 2022-08-19 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
CA2886393C (fr) 2012-09-27 2019-02-26 The Children's Medical Center Corporation Triterpenes pentacycliques destines au traitement de l'obesite
US20160375039A1 (en) 2013-11-26 2016-12-29 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
WO2015153933A1 (fr) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Inhibiteurs hsp 90 pour le traitement de l'obésité et leurs procédés d'utilisation
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (fr) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Conjugués insuline vitamine d
CA2964463C (fr) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Conjugues de vitamine d therapeutiques
EP3481413A4 (fr) * 2016-07-08 2020-01-08 Askgene Pharma, Inc. Protéine de fusion comprenant de la leptine et procédés de production et d'utilisation associés
PL3509624T3 (pl) 2016-09-12 2024-03-25 Amryt Pharmaceuticals Inc. Sposób wykrywania przeciwciał neutralizujących przeciwko leptynie

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
ZA946122B (en) * 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1996023815A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Anticorps contre les produits du gene ob
NZ512083A (en) * 1995-11-22 2003-02-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
WO1997020933A2 (fr) * 1995-12-06 1997-06-12 Schering Corporation VARIANTES MUTATIONNELLES DE PROTEINES DE GENES Ob CHEZ LES MAMMIFERES
JPH09176198A (ja) * 1995-12-28 1997-07-08 Kikkoman Corp 抗肥満タンパク質モノクローナル抗体及びハイブリドーマ
AU2246097A (en) * 1996-01-25 1997-08-20 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
EP0827750A3 (fr) * 1996-08-23 2002-11-20 Eli Lilly And Company Préparations des protéines contre l'obésité
AU1208599A (en) * 1997-10-31 1999-05-24 Eli Lilly And Company Glycosylated obesity protein analogs
DE69921486T2 (de) * 1998-08-10 2006-02-02 Amgen Inc., Thousand Oaks Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility

Also Published As

Publication number Publication date
DE60027409D1 (de) 2006-05-24
WO2000047741A1 (fr) 2000-08-17
EP1151102A1 (fr) 2001-11-07
DE60027409T2 (de) 2007-04-12
JP2002536018A (ja) 2002-10-29
CA2359840C (fr) 2012-10-23
JP4841037B2 (ja) 2011-12-21
ATE323766T1 (de) 2006-05-15
CY1107470T1 (el) 2012-12-19
CA2359840A1 (fr) 2000-08-17
ES2257287T3 (es) 2006-08-01
PT1151102E (pt) 2006-07-31
AU3362300A (en) 2000-08-29
AU781460B2 (en) 2005-05-26
EP1151102B1 (fr) 2006-04-19

Similar Documents

Publication Publication Date Title
CY1107470T1 (el) Συνθεσεις γλυκοσυλιωμενης λεπτινης και σχετικες μεθοδοι
AU2001254624A1 (en) Human coagulation factor vii variants
EP1484339A3 (fr) Protéines de "Domaine de Kunitz" a actvité antikallikreine et acides nucléiques les codant
BRPI0410164A (pt) composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
WO2000034317A3 (fr) Modification de l'immunogenicite de proteines
EP2325205A3 (fr) Cristaux d'anticorps complets et de fragments correspondants et leurs procédés de fabrication et d'utilisation
WO2003059934A3 (fr) Proteines de fusion d'albumine
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
YU48703A (sh) Novi interferonu beta-slični molekuli
CY1112655T1 (el) Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις
AU2003215524A1 (en) Pharmaceutical compositions comprising mannose binding lectin
EP0797999A3 (fr) Formulations de protéine d'obésité
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
HUP0500637A2 (hu) Neublasztin polimer konjugátumai és alkalmazási eljárásai
IL81221A0 (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for preparing said proteins and pharmaceutical compositions containing them
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
HUP0100267A2 (hu) Helicobacter pylori eredetű nukleinsav- és aminosav-szekvenciák és a megfelelő nukleinsavakat vagy peptideket tartalmazó vakcina-készítmények
WO2003008449A8 (fr) Ntb-a, une molecule de surface impliquee dans l'activite des cellules tueuses naturelles
DK1219301T3 (da) Vacciner, som indeholder hybridpolypeptider, der består af mindst to forskellige allergene proteiner
EP0369816A3 (fr) Anticorps monoclonaux spécifiques pour la mucine polymorphe épithéliale humaine
NZ335633A (en) Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
ATE331032T1 (de) Glutamine: fructose-6-phosphat amidotransferase (gfat), ihre herstellung und verwendung
EP1801123A3 (fr) Cristaux d'anticorps complets et de fragments correspondants et leurs procédés de fabrication et d'utilisation
FI964186A (fi) Ei-liittävät gp350/220-variantit